CALGARY, ALBERTA, Recently Jon Hagan, Senior Business Partner in Marketing and Communications at Alberta Innovates, sat down with our CEO Dr. Oliver Bathe. Jon explored the Qualisure commercialization journey with Dr. Bathe and how Qualisure benefited from accessing Alberta Innovates’…
Qualisure Diagnostics is pleased to announce the launch of our first diagnostic test, Thyroid GuidePx® for papillary thyroid cancer, the most common type of thyroid cancer. Thyroid GuidePx® is the first genomic classifier available for papillary thyroid cancer. This test…
Dr. Steven Craig of the University of Wollongong presented data on the molecular subgroups identified by Thyroid GuidePx™ at the 90th Annual Meeting of the American Thyroid Association. The presentation at the virtual meeting, entitled “Molecular Subgroups Identified by Machine…
Dr. Cynthia Stretch (Chief Scientific Officer) presented details on the molecular features of molecular subgroups of papillary thyroid cancer that are identifiable using Thyroid GuidePx™ at the Annual Meeting of the Canadian Association of Surgical Oncologists (CSSO). In her presentation…
Qualisure has submitted an international PCT patent application for the molecular subclassification of papillary thyroid cancer which is ending review. The Patent Cooperation treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible…
Qualisure was awarded a $100,000 voucher from Alberta Innovates to support further development of lead product Thyroid GuidePx™. The voucher will be applied to performing final validation tests of the clinical assay in preparation for clinical implementation. Alberta Innovates vouchers…
Following an extensive evaluation of Qualisure Diagnostics; technology and commercialization plan, the University of Calgary invested in Qualisure Diagnostics Inc. through the UCeed program. The investment will be instrumental in advancing Qualisure’s technology development and commercialization efforts. The support received…
The University of Calgary Department of Oncology and the Arnie Charbonneau Cancer Institute awarded $18,750 to Dr. Bathe and colleagues in endocrine surgery and pathology. The seed grant will be used to test Thyroid GuidePx™ in formalin fixed paraffin embedded…
Qualisure Diagnostics Inc. and Protean BioDiagnostics Inc. together will perform the technical validation essential to launch Thyroid GuidePx™ as a Laboratory Developed Test in the United States. Protean BioDiagnostics is a CAP/CLIA certified lab focused on Precision Oncology. Protean’s commitment…
Qualisure Diagnostics Inc. and OncoHelix Inc. will collaborate to prepare Thyroid GuidePx™ for introduction to the clinic. OncoHelix’s expertise in next generation sequencing (NGS) and Precision Oncology will be leveraged to perform the validation necessary to make this test available…